Amonafide
Amonafide[edit | edit source]
Amonafide, bearing the original designation AS1413, is an investigational drug undergoing study for its potential use in oncology. Recognized by trade names such as Quinamed and Xanafide, Amonafide emerges from the novel category of chemotherapy agents referred to as Naphthalimides. These agents function by inhibiting the topoisomerase enzyme and also intercalating DNA, leading to disruption in the replication processes of cancer cells.
Contents[edit | edit source]
- 1 Chemical Classification
- 2 Mechanism of Action
- 3 Development and Clinical Trials
- 4 FDA Fast Track Status
- 5 Potential Therapeutic Uses
- 6 See Also
- 7 References
Chemical Classification[edit | edit source]
Amonafide is a representative member of the Naphthalimides family of chemotherapeutic agents.
Mechanism of Action[edit | edit source]
At its core, Amonafide functions as a:
- Topoisomerase inhibitor: By inhibiting the action of topoisomerase, Amonafide stalls the DNA replication process, halting the rapid division of cancer cells.
- DNA intercalator: The drug wedges itself between the base pairs in the DNA structure, further hampering the DNA replication and transcription processes.
Development and Clinical Trials[edit | edit source]
Antisoma, a renowned pharmaceutical company, is at the helm of developing Amonafide as a potential anti-cancer therapy. Key milestones in its clinical development include:
- 2008: The drug reached Phase III of clinical trials.
- March 2010: Initiation of Phase III trial targeting secondary Acute Myeloid Leukaemia (AML).
- June 2010: The U.S. Food and Drug Administration (FDA) conferred a Fast Track Status on Amonafide for the treatment of Secondary Acute Myeloid Leukaemia (AML).
FDA Fast Track Status[edit | edit source]
In June 2010, the FDA accorded Amonafide with a Fast Track Status. This designation is reserved for medications with the potential to address unmet medical needs, facilitating a more streamlined review process for the drug.
Potential Therapeutic Uses[edit | edit source]
While the primary focus is on harnessing Amonafide's properties to combat secondary AML, ongoing research is expected to uncover its efficacy in treating other cancer forms as well.
See Also[edit | edit source]
External links[edit | edit source]
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
Amonafide Resources | |
---|---|
|
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
Amonafide Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD